secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tango Therapeutics, Inc. (TNGX)
CIK:        0001819133
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0000950170-25-028345
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tango Therapeutics reports Q4 2024 net loss of $37.7M; cash runway into 3Q 2026
-------------------------------------------------------------------------------

- Net loss of $37.7M for Q4 2024 ($0.35 per share) vs $30.8M loss in Q4 2023; full year net loss $130.3M ($1.19 per share).
- Cash and marketable securities $257.9M as of Dec 31, 2024; expected to fund operations into 3Q 2026.
- TNG462 granted FDA Orphan Drug Designation for pancreatic cancer; Phase 1/2 data update expected in 2025.
- IND for TNG456 cleared; Phase 1/2 enrollment expected 1H 2025; clinical collaboration with Lilly for abemaciclib combination.
- TNG260 proof-of-mechanism established; dose expansion ongoing in lung cancer; clinical update expected 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819133/000095017025028345/0000950170-25-028345-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819133/000095017025028345/tngx-20220810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-028345

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer